Inventor · disambiguated record
Sandra Verploegen
Also filed as: VERPLOEGEN SANDRA
10 granted patents·21 pending applications·101 citations·filing 2009–2025
89Inventor score
Top patents by PatentIndex Score
31 records- 0193US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 0293US9492565B2Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2015·Granted Nov 15, 2016·7 cites·16 claims
- 0392US9168314B2Human antibody drug conjugates against tissue factorSATIJN DAVID·Filed 2011·Granted Oct 27, 2015·29 cites·11 claims
- 0491US11180572B2Dimeric protein with triple mutationsGENMAB BV·Filed 2013·Granted Nov 23, 2021·12 cites·45 claims
- 0590US9714297B2Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2015·Granted Jul 25, 2017·9 cites·29 claims
- 0690US9150658B2Human antibodies against tissue factor and methods of use thereofVERPLOEGEN SANDRA·Filed 2009·Granted Oct 6, 2015·20 cites·43 claims
- 0786US2024294661A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2023·Application pending·0 cites
- 0882US2023416403A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 0980US9540433B2Human antibodies and antibody-drug conjugates against CD74VERPLOEGEN SANDRA·Filed 2012·Granted Jan 10, 2017·6 cites·43 claims
- 1079US2025340669A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 1176US2025145720A1Human igg1 fc region variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 1274US2021395384A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2021·Application pending·0 cites
- 1369US2022323582A1Human antibodies and antibody-drug conjugates against cd74GENMAB AS·Filed 2021·Application pending·0 cites
- 1469US2025066507A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2024·Application pending·0 cites
- 1569US2021171657A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2020·Application pending·0 cites
- 1666US2019315880A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2019·Application pending·0 cites
- 1765US2017136130A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2016·Application pending·0 cites
- 1864US2019169311A1Human Antibodies Against Tissue Factor and Methods of Use ThereofGENMAB AS·Filed 2018·Application pending·0 cites
- 1961US2018044431A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2017·Application pending·0 cites
- 2059US2020199231A1Bispecific antibodies against cd3 and cd20GENMAB AS·Filed 2019·Application pending·0 cites
- 2156US12246025B2Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Granted Mar 11, 2025·0 cites·25 claims
- 2254US2021107980A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Application pending·0 cites
- 2352US2015353636A1Human igg1 fc region variants and uses thereofGENMAB BV·Filed 2013·Application pending·0 cites
- 2451US2021230301A1Dimeric protein with triple mutationsGENMAB BV·Filed 2020·Application pending·0 cites
- 2549US2017173151A1Human antibodies and antibody-drug conjugates against cd74GENMAB AS·Filed 2016·Application pending·0 cites
- 2648US12453781B2Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Granted Oct 28, 2025·0 cites·36 claims
- 2748US2021308208A1Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancerGENMAB AS·Filed 2019·Application pending·0 cites
- 2846US2022387485A1Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2020·Application pending·0 cites
- 2945US2021030888A1Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancerGENMAB AS·Filed 2019·Application pending·0 cites
- 3044US2023027495A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2020·Application pending·0 cites
- 3138US12324841B2Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Granted Jun 10, 2025·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Sandra Verploegen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →